Global Pediatric Neuroblastoma Treatment Market Size study, by Treatment Type (Chemotherapy, Immunotherapy, and Others), by Distribution Channel (Hospital Pharmacies and Retail Pharmacies) and Regional Forecasts 2022-2028

Global Pediatric Neuroblastoma Treatment Market Size study, by Treatment Type (Chemotherapy, Immunotherapy, and Others), by Distribution Channel (Hospital Pharmacies and Retail Pharmacies) and Regional Forecasts 2022-2028

Global Pediatric Neuroblastoma Treatment Market is valued at approximately XX in 2021 and is anticipated to grow with a healthy growth rate of more than 6% over the forecast period 2022-2028. The most common type of extracranial solid tumour in children is neuroblastoma. The rising prevalence of neuroblastoma in children, as well as increased research and development and increased awareness of available cancer treatments, are all contributing to the market's growth. Neuroblastoma is estimated to affect one out of every 7,000 live births, according to a National Cancer Institute article published in February 2022. In children under the age of 15, the annual incidence is 10.54 cases per 1 million. Around 37% of patients are diagnosed as infants, and 90% are under the age of 5, with a median age of 19 months at diagnosis. Furthermore, the government's increasing investments in research and development programmes to develop the medical infrastructure in the paediatric section, as well as increased awareness of paediatric neuroblastoma treatment, are boosting the market growth. Furthermore, increasing investments in evaluating the efficacy of chemotherapy in paediatric neuroblastoma will propel the market forward. For example, in January 2022, Jason Shohet, MD, PhD, was awarded a new two-year USD 300,000 Scholar Hope Grant to focus on drug resistance in neuroblastoma chemotherapy treatments. It is a cancer of the peripheral nervous system that is fatal in children. However, the high cost of paediatric neuroblastoma treatment is a significant impediment to market expansion.

The key regions considered for the global Pediatric Neuroblastoma Treatment market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. Throughout the forecast period, North America is expected to dominate the overall market. The high prevalence of paediatric neuroblastoma in the region, as well as established healthcare infrastructure, are some of the key factors responsible for the region's large market share. Additionally, favourable government initiatives and an increase in the number of research partnerships are expected to drive market growth. The Asia Pacific (APAC) region, on the other hand, will grow at a steady pace over the forecast period. Increased public investment and improvements in healthcare infrastructure will be attributed to this growth.

Major market players included in this report are:
United Therapeutics Corporation
APEIRON Biologics AG
Baxter International
Pfizer, Inc.
Bayer AG
MacroGenics, Inc.
Sartorius AG
CELLECTAR BIOSCIENCES, INC.
PROVECTUS BIOPHARMACEUTICALS, INC.
Y-mAbs Therapeutics, Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment Type:
Chemotherapy
Immunotherapy
Others

By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Pediatric Neuroblastoma Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

United Therapeutics Corporation
APEIRON Biologics AG
Baxter International
Pfizer, Inc.
Bayer AG
MacroGenics, Inc.
Sartorius AG
CELLECTAR BIOSCIENCES, INC.
PROVECTUS BIOPHARMACEUTICALS, INC.
Y-mAbs Therapeutics, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.